JP6761410B2 - グルココルチコイドおよびミネラル・コルチコイドレセプターアンタゴニストを使用する脂肪肝疾患の処置 - Google Patents

グルココルチコイドおよびミネラル・コルチコイドレセプターアンタゴニストを使用する脂肪肝疾患の処置 Download PDF

Info

Publication number
JP6761410B2
JP6761410B2 JP2017520388A JP2017520388A JP6761410B2 JP 6761410 B2 JP6761410 B2 JP 6761410B2 JP 2017520388 A JP2017520388 A JP 2017520388A JP 2017520388 A JP2017520388 A JP 2017520388A JP 6761410 B2 JP6761410 B2 JP 6761410B2
Authority
JP
Japan
Prior art keywords
acid
compounds
liver disease
liver
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017520388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531013A (ja
JP2017531013A5 (OSRAM
Inventor
ジョセフ ケー． ベラノフ，
ジョセフ ケー． ベラノフ，
ヘイゼル ハント，
ヘイゼル ハント，
オノ セー． メイヤ，
オノ セー． メイヤ，
デン ヘフェル， ホセ ファン
デン ヘフェル， ホセ ファン
Original Assignee
コーセプト セラピューティクス， インコーポレイテッド
コーセプト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーセプト セラピューティクス， インコーポレイテッド, コーセプト セラピューティクス， インコーポレイテッド filed Critical コーセプト セラピューティクス， インコーポレイテッド
Publication of JP2017531013A publication Critical patent/JP2017531013A/ja
Publication of JP2017531013A5 publication Critical patent/JP2017531013A5/ja
Application granted granted Critical
Publication of JP6761410B2 publication Critical patent/JP6761410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017520388A 2014-10-15 2015-10-14 グルココルチコイドおよびミネラル・コルチコイドレセプターアンタゴニストを使用する脂肪肝疾患の処置 Active JP6761410B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US62/064,358 2014-10-15
US201462092041P 2014-12-15 2014-12-15
US62/092,041 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (3)

Publication Number Publication Date
JP2017531013A JP2017531013A (ja) 2017-10-19
JP2017531013A5 JP2017531013A5 (OSRAM) 2018-11-22
JP6761410B2 true JP6761410B2 (ja) 2020-09-23

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017520388A Active JP6761410B2 (ja) 2014-10-15 2015-10-14 グルココルチコイドおよびミネラル・コルチコイドレセプターアンタゴニストを使用する脂肪肝疾患の処置

Country Status (22)

Country Link
US (5) US10238659B2 (OSRAM)
EP (2) EP4353310A3 (OSRAM)
JP (1) JP6761410B2 (OSRAM)
KR (1) KR102435956B1 (OSRAM)
CN (2) CN111557942B (OSRAM)
AU (1) AU2015333645B2 (OSRAM)
BR (1) BR112017007860B1 (OSRAM)
CA (1) CA2964625C (OSRAM)
DK (1) DK3206692T3 (OSRAM)
ES (1) ES2978871T3 (OSRAM)
FI (1) FI3206692T3 (OSRAM)
IL (1) IL251729B (OSRAM)
MX (1) MX2017004943A (OSRAM)
NZ (1) NZ731060A (OSRAM)
PH (1) PH12017500710B1 (OSRAM)
PL (1) PL3206692T3 (OSRAM)
PT (1) PT3206692T (OSRAM)
RU (1) RU2718921C2 (OSRAM)
SG (1) SG11201703024VA (OSRAM)
UA (1) UA123537C2 (OSRAM)
WO (1) WO2016061195A1 (OSRAM)
ZA (1) ZA201702813B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
SG11202011948SA (en) * 2018-06-04 2020-12-30 Corcept Therapeutics Inc Pyrimidine cyclohexenyl glucocorticoid receptor modulators
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
US11548856B2 (en) * 2020-05-06 2023-01-10 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
US12144812B2 (en) * 2020-05-06 2024-11-19 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
WO2022140293A1 (en) * 2020-12-21 2022-06-30 Corcept Therapeutics Incorporated Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2022235647A1 (en) * 2021-05-05 2022-11-10 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
ATE463479T1 (de) 2005-05-18 2010-04-15 Merck Sharp & Dohme D-homoandrosta-17-yl-carbamat-derivate als selektive glucocorticoid-rezeptor-liganden
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
WO2007035759A1 (en) * 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
PE20090695A1 (es) 2007-04-13 2009-06-27 Schering Corp Derivados de pirimidindiona como agonistas del receptor de acido nicotinico
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
US12226417B2 (en) 2025-02-18
AU2015333645B2 (en) 2020-01-30
PL3206692T3 (pl) 2024-07-22
AU2015333645A1 (en) 2017-05-04
BR112017007860A2 (pt) 2018-01-16
US20210085682A1 (en) 2021-03-25
EP3206692A4 (en) 2018-05-30
US20160106749A1 (en) 2016-04-21
FI3206692T3 (fi) 2024-05-06
NZ731060A (en) 2023-07-28
CA2964625C (en) 2023-03-07
PT3206692T (pt) 2024-04-30
CN107106562A (zh) 2017-08-29
JP2017531013A (ja) 2017-10-19
CN111557942A (zh) 2020-08-21
RU2017114596A (ru) 2018-11-15
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
CN111557942B (zh) 2023-10-03
SG11201703024VA (en) 2017-05-30
EP3206692A1 (en) 2017-08-23
EP4353310A2 (en) 2024-04-17
EP3206692B1 (en) 2024-04-03
DK3206692T3 (da) 2024-04-29
US11590135B2 (en) 2023-02-28
PH12017500710B1 (en) 2024-01-17
MX2017004943A (es) 2017-07-19
CN107106562B (zh) 2020-08-18
PH12017500710A1 (en) 2017-10-09
KR20170066646A (ko) 2017-06-14
ZA201702813B (en) 2019-05-29
RU2017114596A3 (OSRAM) 2019-05-08
UA123537C2 (uk) 2021-04-21
US20230218621A1 (en) 2023-07-13
CA2964625A1 (en) 2016-04-21
RU2718921C2 (ru) 2020-04-15
IL251729B (en) 2020-03-31
US10238659B2 (en) 2019-03-26
US20190151318A1 (en) 2019-05-23
ES2978871T3 (es) 2024-09-23
IL251729A0 (en) 2017-06-29
EP4353310A3 (en) 2024-06-19
WO2016061195A1 (en) 2016-04-21
BR112017007860B1 (pt) 2023-03-07
KR102435956B1 (ko) 2022-08-23

Similar Documents

Publication Publication Date Title
JP6761410B2 (ja) グルココルチコイドおよびミネラル・コルチコイドレセプターアンタゴニストを使用する脂肪肝疾患の処置
US20250312312A1 (en) Glucocorticoid receptor modulators to treat pancreatic cancer
US20230355610A1 (en) Glucocorticoid receptor modulators to treat cervical cancer
KR20070115879A (ko) 의학 장애의 치료용 ｃｘｃｒ4 길항제
JP7670462B2 (ja) 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
HK40102771A (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
HK1240087A1 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
HK1240087B (zh) 使用糖皮質激素和鹽皮質激素受體拮抗劑的脂肪肝疾病治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200623

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200904

R150 Certificate of patent or registration of utility model

Ref document number: 6761410

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250